Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Tae Yeal Choi is active.

Publication


Featured researches published by Tae Yeal Choi.


Fems Yeast Research | 2010

Prevalence of the VNIc genotype of Cryptococcus neoformans in non-HIV associated cryptococcosis in the Republic of Korea

Young Hwa Choi; Popchai Ngamskulrungroj; Ashok Varma; Edward Sionov; Soo Myung Hwang; Fabian Carriconde; Wieland Meyer; Anastasia P. Litvintseva; Wee Gyo Lee; Jong Hee Shin; Eui Chong Kim; Kyungwon Lee; Tae Yeal Choi; Yeong Seon Lee; Kyung J. Kwon-Chung

PCR fingerprinting and multilocus sequence typing were applied to determine the major molecular types of the Cryptococcus neoformans/Cryptococcus gattii species complex in the Republic of Korea. Of the 78 strains isolated from patients diagnosed with cryptococcosis between 1990 and 2008, 96% were C. neoformans serotype A, mating type MATalpha and molecular type VNI. The remaining 4% were C. gattii, serotype B, mating type MATalpha and either molecular type VGIIb or VGIII. Of the 62 strains with known HIV status, only 14 (22.6%) were isolated from HIV-positive patients and belonged to molecular type VNI. Remarkably, 93% of the C. neoformans isolates had identical PCR fingerprint profiles with the VNIc genotype that has been identified recently as the major genotype among C. neoformans strains in China. Most strains (81.8%) of the VNIc genotype were associated with non-HIV patients compared with strains of the non-VNIc genotype (20%) (P=0.009). Unlike the Chinese strains, a majority (60%) of the non-HIV patients infected with strains of the VNIc genotype in the Republic of Korea had serious underlying conditions, with cancer and liver disease being the most common. This study affirms VNIc to be the most prevalent genotype of C. neoformans isolated from non-HIV patients with cryptococcosis.


International Journal of Antimicrobial Agents | 2009

Wide dissemination of OXA-type carbapenemases in clinical Acinetobacter spp. isolates from South Korea

Kyungwon Lee; Mi-Na Kim; Tae Yeal Choi; Soung-Eun Cho; Seungok Lee; Dong Hee Whang; Dongeun Yong; Yunsop Chong; Neil Woodford; David M. Livermore

Carbapenem-resistant Acinetobacter spp. are being increasingly reported worldwide, including in South Korea, where we examined 144 representative isolates collected in a nationwide hospital survey in 2005. Metallo-beta-lactamases were detected in only 19.4% of isolates, none of which were Acinetobacter baumannii, whereas 74.3% of isolates (mostly A. baumannii) expressed bla(OXA) carbapenemase genes. Among the latter, 47 had bla(OXA-23)-like genes and 56 had upregulated bla(OXA-51)-like variants, including bla(OXA-66), (-83), (-109) and (-115); bla(OXA-115) was a novel variant, detected in two isolates. bla(OXA-72) (bla(OXA-40)-like) was detected in only a single Acinetobacter baylyi isolate, whilst three Acinetobacter calcoaceticus isolates had both bla(VIM-2)-like and bla(OXA-58) genes. Pulsed-field gel electrophoresis (PFGE) suggested the spread of A. baumannii clones with OXA carbapenemases within and between hospitals. In conclusion, the recent increase in imipenem-resistant Acinetobacter spp. from South Korea is mostly due to OXA-type carbapenemases.


Antimicrobial Agents and Chemotherapy | 2007

Association of QnrB Determinants and Production of Extended-Spectrum β-Lactamases or Plasmid-Mediated AmpC β-Lactamases in Clinical Isolates of Klebsiella pneumoniae

Hyunjoo Pai; Mi-Ran Seo; Tae Yeal Choi

ABSTRACT Clinical isolates of Escherichia coli and Klebsiella pneumoniae producing extended-spectrum β-lactamases or plasmid-mediated AmpC β-lactamases were screened for qnrA and qnrB genes. QnrB was present in 54 of 54 DHA-1-producing K. pneumoniae isolates and 10 of 45 SHV-12-producing ones, suggesting that the distribution of plasmids conferring resistance to extended-spectrum cephalosporins and quinolones in clinical isolates of K. pneumoniae is widespread.


International Journal of Antimicrobial Agents | 2012

Association between PCR ribotypes and antimicrobial susceptibility among Clostridium difficile isolates from healthcare-associated infections in South Korea.

Jieun Kim; Jung Oak Kang; Hyunjoo Pai; Tae Yeal Choi

In this study, the association between antimicrobial susceptibility, PCR ribotype and presence of the ermB gene in clinical isolates of Clostridium difficile was investigated. PCR ribotyping and ermB gene PCR were performed on 131 C. difficile isolates. The susceptibility of these isolates to metronidazole, vancomycin, piperacillin/tazobactam (TZP), clindamycin, moxifloxacin and rifaximin was also determined. Use of antibiotics within the previous 2 months was documented. Resistance rates to clindamycin, moxifloxacin and rifaximin were 67.9%, 62.6% and 19.1%, respectively. No metronidazole, vancomycin or TZP resistance was detected. Previous exposure to moxifloxacin was significantly correlated with resistance to this antibiotic, but prior use of clindamycin was not significantly correlated with clindamycin resistance. Sixty-four strains (48.9%) carried the ermB gene, of which all but one (98.5%) were resistant to clindamycin. The clindamycin resistance rates of the common PCR ribotypes (018, 017 and 001) were 91.4%, 100% and 84.2%, respectively, and their moxifloxacin resistance rates were 91.4%, 95.0% and 78.9%, respectively. Resistance rates to rifaximin were 5.7% and 95.0% in ribotype 018 and 017 strains, whilst none of the 001 strains were resistant to rifaximin. In conclusion, the common ribotypes 018, 017 and 001 of C. difficile have high rates of resistance to clindamycin and moxifloxacin, but differ greatly in the frequency of rifaximin resistance.


Infection and Chemotherapy | 2014

Increase in the Prevalence of Carbapenem-Resistant Acinetobacter Isolates and Ampicillin-Resistant Non-Typhoidal Salmonella Species in Korea: A KONSAR Study Conducted in 2011.

Dongeun Yong; Hee Bong Shin; Yong Kyun Kim; Ji-Hyun Cho; Wee Gyo Lee; Gyoung Yim Ha; Tae Yeal Choi; Seok Hoon Jeong; Kyungwon Lee; Yunsop Chong

Background Antimicrobial surveillance is important for providing an up-to-date understanding of the epidemiology of antimicrobial resistance and for creating a forum for rational drug development. In this study, we analyzed antimicrobial test data generated in 2011 by hospitals and commercial laboratories participating in the Korean Nationwide Surveillance of Antimicrobial Resistance program (KONSAR). Materials and Methods Data on the results of susceptibility tests conducted in 32 hospitals and two commercial laboratories were analyzed. Data on isolates from patients admitted to an intensive care unit (ICU) and those admitted to other wards were compared. Intermediate susceptibility was not analyzed and duplicate isolates were excluded. Results Escherichia coli was the most prevalent organism identified in both the hospital and commercial laboratories. Among the hospital isolates, methicillin-resistant Staphylococcus aureus (MRSA), penicillin G-non-susceptible Streptococcus pneumoniae, and ampicillin-resistant Enterococcus faecium remained as prevalent as they were in 2009. The proportion of vancomycin-resistant E. faecium (VR-EFM) slightly decreased from 29% in 2009 to 23% in 2011. Resistance rates of Klebsiella pneumoniae to ceftazidime, cefoxitin, fluoroquinolone, and amikacin were 24%, 14%, 27%, and 8%, respectively. Resistance rates of Pseudomonas aeruginosa to fluoroquinolone, ceftazidime, imipenem, and amikacin were 33%, 20%, 22%, and 16%, respectively, whereas those of Acinetobacter spp. resistance were 71%, 66%, 64, and 51%, respectively. The prevalence of oxyimino-cephalosporin-resistant E. coli and K. pneumoniae, carbapenem-resistant Acinetobacter spp. and P. aeruginosa, MRSA, and VR-EFM among ICU isolates was higher than those among non-ICU isolates. Extended-spectrum β-lactamase-producing E. coli and K. pneumoniae, imipenem-resistant P. aeruginosa, and VR-EFM were more prevalent among isolates from commercial laboratories than those from hospitals. Resistance rates of K. pneumoniae to ceftazidime and amikacin decreased from 32% and 24% in 2005 to 24% and 8% in 2011, respectively. The resistance rate of P. aeruginosa to amikacin decreased from 22% in 2005 to 16% in 2011. The proportion of imipenem-resistant Acinetobacter spp. increased from 16% in 2005 to 64% in 2011. Conclusions The prevalence of MRSA, penicillin G-non-susceptible S. pneumoniae, and ampicillin-resistant E. faecium among clinical isolates tested in laboratories remained high. Multidrug resistance was more prevalent among isolates from ICUs. The prevalence of ceftazidime-resistant and amikacin-resistant K. pneumoniae and amikacin-resistant P. aeruginosa decreased after 2005, while the prevalence of imipenem-resistant Acinetobacter spp. increased.


Infection Control and Hospital Epidemiology | 2006

A Nosocomial Outbreak of Escherichia coli Producing CTX‐M‐15 and OXA‐30 β‐Lactamase

Hyunjoo Pai; Mi Ran Kim; Bs Mi‐Ran Seo; Tae Yeal Choi; Sung Hee Oh

During a survey of the prevalent subtypes of extended-spectrum beta -lactamases in a university hospital in Korea, a nosocomial outbreak of Escherichia coli producing CTX-M-15 and OXA-30 beta -lactamases was detected. The outbreak comprised various infections, including bloodstream infections and colonization, and persisted for several months in various areas of the hospital.


Journal of Korean Medical Science | 2014

Susceptibility of Escherichia coli from Community-Acquired Urinary Tract Infection to Fosfomycin, Nitrofurantoin, and Temocillin in Korea

Mi Ran Seo; Seong Jong Kim; Yeonjae Kim; Jieun Kim; Tae Yeal Choi; Jung Oak Kang; Seong Heon Wie; Moran Ki; Young Kyun Cho; Seung Kwan Lim; Jin Seo Lee; Ki Tae Kwon; Hyuck Lee; Hee Jin Cheong; Dae Won Park; Seong Yeol Ryu; Moon Hyun Chung; Hyunjoo Pai

With increase of multi-drug resistant Escherichia coli in community-acquired urinary tract infections (CA-UTI), other treatment option with a therapeutic efficacy and a low antibiotic selective pressure is necessary. In this study, we evaluated in vitro susceptibility of E. coli isolates from CA-UTI to fosfomycin (FM), nitrofurantoin (NI), temocillin (TMO) as well as trimethoprim-sulfamethoxazole (SMX), ciprofloxacin (CIP) and cefepime (FEP). The minimal inhibitory concentrations were determined by E-test or agar dilution method according to the Clinical and Laboratory Standards Institute guidelines, using 346 E. coli collected in 12 Korean hospitals from March 2010 to February 2011. FM, NI and TMO showed an excellent susceptibility profile; FM 100% (346/346), TMO 96.8% (335/346), and NI 99.4% (344/346). Conversely, resistance rates of CIP and SMX were 22% (76/346) and 29.2% (101/349), respectively. FEP still retained an activity of 98.5%. In Korea, NI and TMO in addition to FM are a good therapeutic option for uncomplicated CA-UTI, especially for lower UTI. Graphical Abstract


Mycoses | 2007

Susceptibility and trailing growth of Candida albicans to fluconazole: results of a Korean multicentre study

Mi-Kyung Lee; Hye Ryoun Kim; Jung Oak Kang; Mi Na Kim; Eui Chong Kim; Jae Seok Kim; Jin Ju Kim; Yeon Joon Park; Wonkeun Song; Jong Hee Shin; Kyu Man Lee; Nam Yong Lee; Miae Lee; Wee Gyo Lee; Chang Kyu Lee; Hee Joo Lee; Chulhun L. Chang; Tae Yeal Choi

The work reported here is the first nationwide, multicenter surveillance study conducted in Korea to obtain data on fluconazole susceptibility of Candida albicans (C. albicans) isolates. A total of 1137 isolates of C. albicans obtained from 17 university hospitals in South Korea during the 6‐month period, July through December 2004, were tested. No resistant strains were observed in any of the isolates. Only five of the 1137 isolates (0.44%) of C. albicans were found to be susceptible dose dependent, with all remaining strains (99.56%) susceptible to fluconazole. Trailing growth at 48 h was found in only four isolates (0.35%).


Infection and Chemotherapy | 2013

Clinical and Microbiologic Characteristics of Clostridium difficile Infection Caused by Binary Toxin Producing Strain in Korea

Jieun Kim; Mi Ran Seo; Jung Oak Kang; Tae Yeal Choi; Hyunjoo Pai

Background Binary toxin-producing Clostridium difficile infections (CDI) are known to be more severe and to cause higher case fatality rates than those by binary toxin-negative isolates. There has been few data of binary toxin-producing CDI in Korea. Objective of the study is to characterize clinical and microbiological trait of CDI cause by binary-toxin producing isolates in Korea. Materials and Methods From September 2008 through January 2010, clinical characteristics, medication history and treatment outcome of all the CDI patients were collected prospectively. Toxin characterization, PCR ribotyping and antibiotic susceptibility were performed with the stool isolates of C. difficile. Results During the period, CDI caused by 11binary toxin-producing isolates and 105 toxin A & toxin B-positive binary toxin-negative isolates were identified. Comparing the disease severity and clinical findings between two groups, leukocytosis and mucoid stool were more frequently observed in patients with binary toxin-positive isolates (OR: 5.2, 95% CI: 1.1 to 25.4, P = 0.043; OR: 7.6, 95% CI: 1.6 to 35.6, P = 0.010, respectively), but clinical outcome of 2 groups did not show any difference. For the risk factors for acquisition of binary toxin-positive isolates, previous use of glycopeptides was the significant risk factor (OR: 6.2, 95% CI: 1.4 to 28.6, P = 0.019), but use of probiotics worked as an inhibitory factor (OR: 0.1, 95% CI: 0.0 to 0.8; P = 0.026). PCR ribotypes of binary toxinproducing C. difficile showed variable patterns: ribotype 130, 4 isolates; 027, 3 isolates; 267 and 122, 1 each isolate and unidentified C1, 2 isolates. All 11 binary toxin-positive isolates were highly susceptible to clindamycin, moxifloxacin, metronidazole, vancomycin and piperacillin-tazobactam, however, 1 of 11 of the isolates was resistant to rifaximin. Conclusions Binary toxin-producing C. difficile infection was not common in Korea and those isolates showed diverse PCR ribotypes with high susceptibility to antimicrobial agents. Glycopeptide use was a risk factor for CDI by those isolates.


International Journal of Antimicrobial Agents | 2009

Prevalence and spread of integron-IS26 in imipenem-resistant Acinetobacter baumannii clinical isolates in South Korea

Ok Yeon Jeoung; Sook Jin Jang; Xue Min Li; Geon Park; Dongeun Yong; Jung Oak Kang; Sun Hoe Koo; Won Yong Kim; Eui Chong Kim; Yeon Joon Park; Won Keun Song; Jong Hee Shin; Ji Young Ahn; Young Uh; Kyungwon Lee; Sung Hee Lee; Wee Gyo Lee; Hye Soo Lee; Tae Yeal Choi; Ji Hyun Cho; Seok Hoon Jeong; Seong Geon Hong; Jong-Wook Lee; Dong-Min Kim; Chulhun L. Chang; Sung Heui Shin; Dae Soo Moon; Young Jin Park

1] Hecht DW. Prevalence of antibiotic resistance in anaerobic bacteria: worrisome developments. Clin Infect Dis 2004;39:92–7. 2] Podglajen I, Breuil J, Bordon F, Gutmann L, Collatz E. A silent carbapenemase gene in strains of Bacteroides fragilis can be expressed after a one-step mutation. FEMS Microbiol Lett 1992;70:21–9. 3] Clinical and Laboratory Standards Institute. Methods for antimicrobial susceptibility testing of anaerobic bacteria; approved standard. 7th ed. Document M11-A7. Wayne, PA: CLSI; 2007. 4] Thompson JS, Malamy MH. Sequencing the gene for an imipenem–cefoxitinhydrolyzing enzyme (CfiA) from Bacteroides fragilis TAL2480 reveals strong similarity between CfiA and Bacillus cereus -lactamase II. J Bacteriol 1990;172:2584–93. 5] Kato N, Yamazoe K, Han C-G, Ohtsubo E. New insertion sequence elements in the upstream region of cfiA in imipenem-resistant Bacteroides fragilis strains. Antimicrob Agents Chemother 2003;47:979–85. 6] Hedberg M, Nord CE; ESCMID Study Group on Antimicrobial Resistance in Anaerobic Bacteria. Antimicrobial susceptibility of Bacteroides fragilis group isolates in Europe. Clin Microbiol Infect 2003;9:475–88. 7] Sóki J, Edwards R, Hedberg M, Fang H, Nagy E, Nord CE. ESCMID Study Group on Antimicrobial Resistance in Anaerobic Bacteria. Examination of cfiA-mediated carbapenem resistance in Bacteroides fragilis strains from a European susceptibility survey. Int J Antimicrob Agents 2006;28:497–502.

Collaboration


Dive into the Tae Yeal Choi's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Eui Chong Kim

Seoul National University

View shared research outputs
Top Co-Authors

Avatar

Jong Hee Shin

Chonnam National University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Ji Young Ahn

Soonchunhyang University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge